AbbVie’s (ABBV) telisotuzumab adizutecan, a treatment for gastric and gastro-esophageal junction cancer, received FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Study on Crohn’s Disease Therapies: What Investors Need to Know
- AbbVie’s Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment
- AbbVie’s Phase 3b Study on Elagolix for Uterine Fibroids: A Market Game-Changer?
- AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer?
- AbbVie Explores New Horizons with Pediatric IBS-D Treatment Study